Transmedics Group, Inc. insider trading
Every open-market purchase and sale by Transmedics Group, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Transmedics Group, Inc.’s insiders pay?
From November 13, 2019 to September 14, 2026, 17 insiders reported 6 open-market purchases and 39 sales not made under a pre-set plan in Transmedics Group, Inc. Twelve months after each purchase was reported, the shares were +52.1% against the S&P 500 on average (median +40.4%), over 4 purchases with a full year of prices; 50% beat the index. After sales, the shares moved −16.8% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 14, 2019 into $26,111 by November 2, 2026, +14.8% a year. It held shares 57% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,290 (+8.2% a year), and held throughout $27,009 (+15.4%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Weill David | Director | 3 | +40.4% (2) | 50% | 7 | −28.3% (5) | September 14, 2026 |
| Hassanein Waleed H | President & CEO | 2 | −54.4% (1) | 0% | 3 | −22.5% (3) | November 18, 2025 |
| Provost Miriam | VP, Global Regulatory Affairs | 0 | — | — | 5 | +26.2% (5) | December 15, 2023 |
| Ranganath Anil P. | See remarks | 0 | — | — | 4 | −58.3% (2) | March 4, 2026 |
| Basile Edward M | Director | 0 | — | — | 3 | −24.3% (3) | June 7, 2024 |
| Corcoran Nicholas | See remarks | 0 | — | — | 3 | −37.0% (2) | March 4, 2026 |
| Gordon Stephen | Chief Financial Officer | 0 | — | — | 2 | −20.7% (2) | May 31, 2024 |
| Hernandez Gerardo | Chief Financial Officer | 0 | — | — | 2 | — | March 4, 2026 |
| Lovell Stephanie | Director | 0 | — | — | 2 | +3.8% (1) | March 6, 2026 |
| Tobin James R | Director | 0 | — | — | 2 | −32.2% (2) | August 9, 2024 |
| Abrams Capital Management, LLC | 10% owner | 0 | — | — | 1 | −63.8% (1) | February 10, 2021 |
| Carey John F | VP of Operations | 0 | — | — | 1 | −58.7% (1) | March 11, 2021 |
| Damme Laura | VP, Clinical Affairs | 0 | — | — | 1 | +14.2% (1) | December 16, 2022 |
| Gunderson Thomas J. | Director | 0 | — | — | 1 | — | June 17, 2026 |
| Kania Edwin | Director | 1 | +182.2% (1) | 100% | 0 | — | November 30, 2021 |
| Khayal Tamer I | Chief Commercial Officer | 0 | — | — | 1 | +86.6% (1) | March 5, 2025 |
| United Therapeutics Corp | 10% owner | 0 | — | — | 1 | −37.3% (1) | December 10, 2019 |
When several insiders traded Transmedics Group, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Transmedics Group, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 5 selling crowds, −31.1%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| March 31, 2026 | 5 selling | −46.7% | −33.9% | not yet |
| December 31, 2025 | 3 selling | −13.7% | −52.2% | not yet |
| May 31, 2024 | 3 selling | +16.0% | −51.4% | −19.3% |
| December 30, 2022 | 4 selling | +13.9% | +15.8% | −3.1% |
| March 31, 2021 | 3 selling | −28.4% | −33.7% | −55.0% |